GENEVA (AP) — Swiss pharmaceutical giant Novartis AG defended a range of flu drugs that have been banned in Italy, while posting virtually flat third quarter profits as new drugs offset patent expirations.

The Basel-based company said Thursday it still had “confidence in the safety and efficacy of its seasonal influenza vaccines Agrippal and Fluad manufactured in Italy.”